Pulse Biosciences to Host Analyst Event on April 25, 2026

Key Terms

nanosecond pulsed field ablation medical

Nanosecond pulsed field ablation is a medical technique that uses extremely short, high‑voltage electrical pulses—each lasting billionths of a second—to selectively disable small areas of tissue, most often to treat irregular heart rhythms. Like a precise, ultra‑brief electric zap that spares surrounding structures, it matters to investors because it can shorten procedure time, reduce complications and recovery, and therefore reshape demand, pricing and adoption for cardiac ablation devices and related services.

atrial fibrillation medical

Atrial fibrillation is a common heart rhythm problem in which the heart’s upper chambers quiver instead of delivering steady, strong pumps, like a washing machine on an unbalanced cycle. It matters to investors because it increases use of medications, medical devices, hospital care and long‑term monitoring, drives demand for new treatments and diagnostics, and can affect healthcare costs, regulatory decisions and revenue prospects across drug, device and insurance markets.

cardiac catheter medical

A cardiac catheter is a thin, flexible tube threaded through a blood vessel into the heart to diagnose or treat heart problems, such as measuring pressure, taking images, opening blocked arteries, or delivering devices. Investors care because the need for cath-based procedures drives demand for medical devices, hospital services and drugs, and outcomes, regulatory approvals or changes in treatment guidelines can quickly affect sales, costs and valuation in related healthcare companies.

Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to host an analyst event following the presentation of its late-breaking data at the Heart Rhythm Society on April 25, 2026, in Chicago, Illinois.

Management will highlight the late-breaking data from its European feasibility study for the treatment of atrial fibrillation and discuss its ongoing clinical program for the nPulse Cardiac Catheter system.

The Analyst Event will be held in hybrid format with a simultaneous online webcast. Those interested in attending in person are invited to reach out to register by contacting the investor relations department at ir@pulsebiosciences.com. Webcast attendees are encouraged to log on in advance of 12:45 PM CT on Saturday, April 25, 2026. A replay will also be available following the event on the 'Events Calendar and Presentations' page of the company's investor website at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260417738130/en/

Investor Contact:
Pulse Biosciences, Inc.
Jon Skinner, CFO
IR@pulsebiosciences.com

Or

Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com

Source: Pulse Biosciences